Loading...
XHKG9926
Market cap6.92bUSD
Dec 23, Last price  
60.00HKD
1D
-1.40%
1Q
-1.32%
IPO
118.18%
Name

Akeso Inc

Chart & Performance

D1W1MN
XHKG:9926 chart
P/E
24.88
P/S
11.15
EPS
2.26
Div Yield, %
0.00%
Shrs. gr., 5y
1.88%
Rev. gr., 5y
337.43%
Revenues
4.53b
+440.35%
2,826,00070,879,0000225,626,000837,656,0004,526,253,000
Net income
2.03b
P
-140,053,000-281,762,000-1,036,374,000-1,074,933,000-1,168,393,0002,028,300,000
CFO
2.47b
P
-123,417,000-219,595,000-617,775,000-1,001,238,000-1,240,413,0002,467,773,000

Profile

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC). It is also developing AK105, a PD-1 monoclonal antibody to treat NSCLC, NPC, classic Hodgkin's lymphoma (R/R cHL), HCC, head and neck cancer, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, TNBC, HNSCC, R/R cHL, NPC, NSCLC, and solid tumors/lymphoma; AK119, a CD73 monoclonal antibody for treating solid tumors; and AK109, a VEGFR-2 monoclonal antibody to treat solid tumors and gastric cancer. In addition, the company develops AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis and asthma, and eosinophilic esophagitis; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia. Further, its preclinical product includes AK127, a TIGIT monoclonal antibody to treat solid tumors; and AK115, a NGF monoclonal antibody. The company has collaboration agreements with Pfizer Pharmaceuticals, AstraZeneca Pharmaceuticals, and MD Anderson Medical Institute. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.
IPO date
Apr 24, 2020
Employees
2,520
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
4,526,253
440.35%
837,656
271.26%
225,626
 
Cost of revenue
2,477,749
2,177,880
1,575,840
Unusual Expense (Income)
NOPBT
2,048,504
(1,340,224)
(1,350,214)
NOPBT Margin
45.26%
Operating Taxes
174
(253,823)
(183,193)
Tax Rate
0.01%
NOPAT
2,048,330
(1,086,401)
(1,167,021)
Net income
2,028,300
-273.60%
(1,168,393)
8.69%
(1,074,933)
3.72%
Dividends
Dividend yield
Proceeds from repurchase of equity
500,466
940,310
BB yield
Debt
Debt current
405,027
451,877
53,452
Long-term debt
2,608,994
1,433,130
813,824
Deferred revenue
871,682
159,566
63,858
Other long-term liabilities
(1,421,278)
(803,733)
Net debt
310,929
(416,111)
(1,778,140)
Cash flow
Cash from operating activities
2,467,773
(1,240,413)
(1,001,238)
CAPEX
(879,490)
(775,642)
(712,126)
Cash from investing activities
(3,997,250)
(889,747)
(579,585)
Cash from financing activities
960,891
1,485,850
1,586,555
FCF
(1,448,208)
(1,798,457)
(1,860,910)
Balance
Cash
2,397,612
2,291,118
2,645,416
Long term investments
305,480
10,000
Excess cash
2,476,779
2,259,235
2,634,135
Stockholders' equity
(2,064,567)
(2,037,360)
(726,783)
Invested Capital
10,445,928
5,361,204
4,185,941
ROIC
25.92%
ROCE
24.44%
EV
Common stock shares outstanding
837,821
824,990
815,932
Price
Market cap
EV
EBITDA
2,191,272
(1,236,660)
(1,293,206)
EV/EBITDA
Interest
86,987
43,290
10,352
Interest/NOPBT
4.25%